A nucleoside phosphonamide monomer of a 2'-carbon chain-extended threonine analogue, its preparation method and application

By preparing nucleoside phosphonamide monomers of 2'-carbon chain extended threonine analogs, the problem of insufficient enzyme resistance of oligonucleotides was solved, achieving high stability and selective RNA binding in human serum and snake venom phosphodiesterase, which is suitable for RNA-targeted drugs and diagnostic reagents.

CN123106798APending Publication Date: 2026-11-17SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510620986.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Oligonucleotides prepared from existing nucleoside phosphoramide monomers have insufficient enzyme resistance, especially their stability in human serum and snake venom phosphodiesterase needs to be improved.

Method used

Nucleoside phosphonamide monomers with 2'-carbon chain-extended threonine analogs are prepared through specific chemical reaction steps, including the use of catalysts, reducing agents, oxidizing agents and protecting groups, to form nucleoside phosphonamide monomers with a 2'-deoxy-2'-CH2OH-TNA skeleton.

Benefits of technology

The prepared oligonucleotides exhibit 300 times greater stability in human serum than natural homologous DNA and 400 times greater stability in snake venom phosphodiesterase. They possess the ability to selectively bind RNA and are suitable for RNA-targeted drugs and diagnostic reagents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106798A_ABST
    Figure CN123106798A_ABST
Patent Text Reader

Abstract

This invention discloses a 2'-carbon chain-extended threonine analog nucleoside phosphonamide monomer, its preparation method, and its applications, belonging to the fields of chemistry and molecular biology. The 2'-carbon chain-extended threonine analog nucleoside phosphonamide monomer includes any one of compounds with structures shown in Formula 1 or salts of said compounds. This invention designs a novel modification strategy, using 2'-deoxy-2'-hydroxymethyl(CH2OH)-TNA as the backbone to design the nucleoside phosphonamide monomer. The oligonucleotides prepared using this monomer are versatile and exhibit significantly improved stability against nucleases, while also possessing the ability to selectively bind RNA. Therefore, they can be used to prepare nucleic acid drugs and diagnostic reagents, particularly in the development of RNA-targeted drugs and viral detection and diagnosis. Furthermore, developing a new route for synthesizing nucleoside monomers with the 2'-deoxy-2'-CH2OH-TNA backbone significantly simplifies the process, improves efficiency, and facilitates widespread application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of chemistry and molecular biology, specifically relating to a nucleoside phosphonamide monomer of a 2'-carbon chain extended threonine nucleic acid analog, its preparation method, and its application. Background Technology

[0002] Small nucleic acid drugs (also known as oligonucleotide drugs) are short chains of nucleic acids composed of a dozen to several dozen nucleotides linked together. They mainly include antisense oligonucleotides (ASO), small interfering RNA (siRNA), aptamers, and small activating RNA (saRNA). Compared with traditional small molecule and antibody drugs, small nucleic acid drugs have many advantages, such as abundant target sites, simple development, strong targeting specificity, long-lasting action, low risk of drug resistance, and broad therapeutic areas, making them a highly sought-after area in new drug development in recent years. However, small nucleic acid drugs based on natural structures typically face several challenges in clinical application. First, they have poor in vivo stability; natural nucleic acids are highly sensitive to nucleases and are easily degraded by nucleases in plasma and tissues. Second, they have poor membrane permeability; due to their multi-anionic nature, they heavily rely on delivery systems. Third, they have weak in vivo targeting; they cannot precisely target specific cells or tissues, potentially leading to off-target effects and causing potential immune stimulation, inflammation, or toxicity. Therefore, in order to ensure the metabolic stability and efficacy of oligonucleotide drugs, artificial nucleic acids and chemical modifications are considered an essential approach for developing nucleic acid drugs.

[0003] Currently, common chemical modifications in ASO drugs mainly involve modifications to bases, phosphate backbones, and sugar rings. For example, Chinese patent CN118271378A discloses a sugar ring-modified nucleoside phosphoramidide monomer, its preparation method, and its application. Using 3'-deoxyapigenin as the backbone, a sugar ring-modified nucleoside phosphoramidide monomer was obtained. The oligonucleotides prepared using this nucleoside phosphoramidide monomer are versatile and exhibit significantly improved stability against nucleases. However, the oligonucleotides prepared from this nucleoside phosphoramidide monomer show approximately 29 times the enzyme resistance of natural homologous DNA in both human serum and snake venom phosphodiesterase, indicating that enzyme resistance still needs improvement. Summary of the Invention

[0004] In order to overcome the shortcomings of the prior art, the present invention aims to provide a nucleoside phosphonamide monomer of a 2'-carbon chain extended threonine nucleic acid analog, its preparation method and application, so as to solve the technical problem that the enzyme resistance of oligonucleotides prepared by existing nucleoside phosphonamide monomers needs to be improved.

[0005] To achieve the above objectives, the present invention employs the following technical solution:

[0006] In a first aspect, the present invention discloses a nucleoside phosphonamide monomer of a 2'-carbon chain-extended threonine analogue, comprising any one of a compound having the structure shown in Formula 1 or a salt of said compound;

[0007]

[0008] in:

[0009] R1 is selected from any one of natural bases, non-natural bases, modified bases, or their salts;

[0010] R2 and R3 are each independently selected from alkyl groups having 1 to 4 carbon atoms;

[0011] DMTr is 4,4'-dimethoxytriphenylmethyl.

[0012] A second aspect of the present invention discloses a method for preparing the nucleoside phosphonamide monomer of the above-mentioned 2'-carbon chain extended threonine analogue, comprising the following steps:

[0013] Step 1: In the presence of a catalyst, react substrate I with ethyl glyoxylate, and then reduce the resulting product in the presence of a reducing agent to obtain compound II and / or its isomers.

[0014] Step 2: Compound II and / or its isomers undergo an intramolecular cyclization reaction under acidic conditions, and are then crystallized to obtain compound III and / or its isomers.

[0015] Step 3: Compound III and / or its isomers undergo a ring-opening reaction in the presence of a reducing agent to obtain compound IV and / or its isomers;

[0016] Step 4: In the presence of a catalyst, compound IV and / or its isomers are reacted with a 1,2-o-dihydroxy protecting agent, followed by the introduction of an acyl protecting group, and finally a reduction reaction is carried out in the presence of a reducing agent to obtain compound V and / or its isomers.

[0017] Step 5: Oxidize compound V and / or its isomers in the presence of an oxidizing agent. The resulting oxides are deprotected and cyclized intramolecularly under acidic conditions to obtain compound VI and / or its isomers.

[0018] Step 6: In the presence of a protective reagent, react compound VI and / or its isomers with R1 to obtain compound VII and / or its isomers;

[0019] Step 7: Remove the protecting group from the sugar ring site of compound VII and / or its isomers under alkaline conditions, and react them with 4,4'-dimethoxytriphenylchloro under the catalysis of a catalyst;

[0020] Step 8: Use the product from step 7 to perform a phosphonamide reaction to obtain a nucleoside phosphonamide monomer of a threonine analog with an extended 2'-carbon chain.

[0021] The structural formulas of compounds I through VII are shown below, where W1, W2, W3, W4, W5, W6, W7, and W8 are each independently selected from hydrogen or protecting groups:

[0022]

[0023] Preferably, in step 1, the catalyst is selected from L-proline and / or its derivatives; the reducing agent is selected from sodium borohydride and / or lithium aluminum hydride; in step 3, the reducing agent is selected from sodium borohydride; in step 4, the catalyst is selected from p-toluenesulfonic acid; in step 5, the oxidizing agent is selected from 2,2,6,6-tetramethylpiperidine-1-oxy radical; and in step 6, the protecting agent includes N,O-bis(trimethylsilyl)acetamide.

[0024] Preferably, in step 7, the catalyst includes 4-dimethylaminopyridine and / or triethylamine, the solvent for the reaction includes dichloromethane or pyridine, the reaction is carried out under an inert gas protection environment, the inert gas includes nitrogen and / or argon, the reaction temperature is 10-50°C, and the time is 2-12 h.

[0025] Preferably, in step 8, the catalyst for the phosphonium amidation reaction includes triethylamine and / or N,N-diisopropylethylamine, the phosphonium amidation reagent for the phosphonium amidation reaction includes 2-cyanoethyl N,N-diisopropylchlorophosphonium amidation, and the temperature of the phosphonium amidation reaction is 10-25°C, and the time is 1-6 h.

[0026] A third aspect of the present invention discloses the application of the above-mentioned 2'-carbon chain extended threonine analog nucleoside phosphonamide monomer in the preparation of oligonucleotides, wherein the enzyme resistance of the oligonucleotides is 300 to 400 times that of natural oligonucleotides.

[0027] Preferably, the oligonucleotide can selectively bind to RNA and does not hybridize with DNA.

[0028] A fourth aspect of the present invention discloses an oligonucleotide, wherein the raw materials for preparing the oligonucleotide include the nucleoside phosphonamide monomer of the 2'-carbon chain extended threonine analog as described in claim 1.

[0029] Preferably, the enzyme resistance of the oligonucleotide is 300 to 400 times that of the natural oligonucleotide.

[0030] Preferably, the oligonucleotide is not completely degraded in human serum for 72 hours.

[0031] Preferably, the oligonucleotide is not completely degraded in snake venom phosphodiesterase for 72 hours.

[0032] A fifth aspect of the present invention discloses a method for preparing oligonucleotides, the method comprising synthesizing oligonucleotides using nucleoside phosphonamide monomers of the 2'-carbon chain extended threonine analogues of claim 1 as raw materials.

[0033] A sixth aspect of the present invention discloses the use of 2'-carbon chain extended threonine analog nucleoside phosphonamide monomers or oligonucleotides in the preparation of nucleic acid drugs, virus detection reagents, RNA localization and imaging reagents, or drug delivery systems.

[0034] Preferably, the nucleic acid drug is an RNA-targeting drug.

[0035] A seventh aspect of the present invention discloses a nucleic acid pharmaceutical composition comprising a nucleoside phosphonamide monomer of the above-described 2'-carbon chain extended threonine analogue or the above-described oligonucleotide.

[0036] Preferably, the nucleic acid drug composition further includes pharmaceutically acceptable excipients.

[0037] Compared with the prior art, the present invention has the following beneficial effects:

[0038] This invention provides a nucleoside phosphonamide monomer for a 2'-carbon chain-extended threonine nucleic acid analog, obtained by modifying the sugar ring with a 2'-deoxy-2'-CH2OH-TNA backbone. The oligonucleotides prepared from this monomer exhibit versatility, with resistance to human serum approximately 300 times that of natural homologous DNA and resistance to snake venom phosphodiesterase approximately 400 times that of natural homologous DNA. Compared to natural DNA, enzyme resistance is improved by orders of magnitude, enabling its use in the development of small nucleic acid drugs and diagnostic reagents. Furthermore, the oligonucleotides prepared from this monomer possess the ability to selectively bind RNA and do not hybridize with DNA, making them suitable for the development of RNA-targeted drugs, virus detection and diagnosis, RNA localization and imaging, and drug delivery. This provides novel molecular entities and new ideas for the development of novel antisense nucleic acid systems.

[0039] This invention provides a method for preparing nucleoside phosphonamide monomers of 2'-carbon chain extended threonine analogs. The method uses 2'-deoxy-2'-CH2OH-TNA as the backbone to design nucleoside phosphonamide monomers. The raw materials are readily available, and the method can be prepared in large quantities. The process is simple and has high production efficiency. It is suitable for the preparation of nucleoside phosphonamide monomers of 2'-carbon chain extended threonine analogs at a scale of 10-100g. Attached Figure Description

[0040] Figure 1 Compound 6 in Example 1 1 H NMR spectrum;

[0041] Figure 2 Compound 6 in Example 1 13 C NMR spectrum;

[0042] Figure 3 For compound 10a in Example 1 31 P NMR spectrum;

[0043] Figure 4 For compound 10b in Example 1 31 P NMR spectrum;

[0044] Figure 5 For compound 10c in Example 1 31 P NMR spectrum;

[0045] Figure 6 For compound 10d in Example 1 31 P NMR spectrum;

[0046] Figure 7 The molecular weight diagram of the fully modified oligonucleotide ON-1 in Example 2;

[0047] Figure 8 The image shows the serum resistance test electrophoresis diagram of the oligonucleotide ON-1 in Example 3; where A is the natural DNA oligonucleotide ON-2 and B is the fully modified oligonucleotide ON-1.

[0048] Figure 9 The image shows an electrophoresis diagram of the snake venom resistance phosphodiesterase experiment of oligonucleotide ON-1 in Example 3; where A is the natural DNA oligonucleotide ON-2 and B is the fully modified oligonucleotide ON-1.

[0049] Figure 10 The diagram shows the thermostability binding results of oligonucleotide ON-1 with complementary natural DNA oligonucleotide ON-3 and complementary natural RNA oligonucleotide ON-4. Detailed Implementation

[0050] To enable those skilled in the art to understand the features and effects of the present invention, the following descriptions and definitions are only general descriptions of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used herein have the ordinary meaning understood by those skilled in the art regarding the present invention, and in the event of any conflict, the definitions in this specification shall prevail.

[0051] The theories or mechanisms described and disclosed herein, whether right or wrong, should not in any way limit the scope of the invention, that is, the contents of the invention can be implemented without being limited by any particular theory or mechanism.

[0052] In this document, all features defined by numerical ranges or percentage ranges, such as numerical values, quantities, contents, and concentrations, are for the sake of brevity and convenience only. Accordingly, descriptions of numerical ranges or percentage ranges should be considered as covering and specifically disclosing all possible sub-ranges and individual numerical values ​​(including integers and fractions) within those ranges.

[0053] In this article, unless otherwise specified, “contains,” “includes,” “containing,” “has,” or similar terms cover the meanings of “composed of” and “mainly composed of,” for example, “A contains a” covers the meanings of “A contains a and others” and “A contains only a.”

[0054] For the sake of brevity, not all possible combinations of the technical features in each implementation scheme or embodiment are described herein. Therefore, as long as there is no contradiction in the combination of these technical features, the technical features in each implementation scheme or embodiment can be combined arbitrarily, and all possible combinations should be considered within the scope of this specification.

[0055] In this article, "TNA" in the backbone 2'-deoxy-2'-CH2OH-TNA stands for Threose Nucleic Acid.

[0056] The present invention provides a nucleoside phosphonamide monomer of a 2'-carbon chain extended threonine analogue, comprising any one of a compound with the structure shown in Formula 1, a salt of the compound, or an isomer of the compound;

[0057]

[0058] in:

[0059] R1 is selected from any one of natural bases, non-natural bases, modified bases, or their salts;

[0060] R2 and R3 are each independently selected from alkyl groups having 1 to 4 carbon atoms;

[0061] DMTr is 4,4'-dimethoxytriphenylmethyl.

[0062] This invention also provides a method for preparing the nucleoside phosphonamide monomer of the above-mentioned 2'-carbon chain extended threonine analogue, designed with 2'-deoxy-2'-CH2OH-TNA as the backbone, including the following steps:

[0063] Step 1: In the presence of a catalyst, react substrate I with ethyl glyoxylate, and then reduce the resulting product in the presence of a reducing agent to obtain compound II and / or its isomers.

[0064] The catalyst is selected from L-proline and / or its derivatives; the reducing agent is selected from sodium borohydride and / or lithium aluminum hydride.

[0065] Step 2: Compound II and / or its isomers undergo an intramolecular cyclization reaction under acidic conditions, and compound III and / or its isomers are obtained by crystallization.

[0066] Step 3: Compound III and / or its isomers undergo a ring-opening reaction in the presence of a reducing agent to obtain compound IV and / or its isomers;

[0067] The reducing agent is selected from sodium borohydride;

[0068] Step 4: In the presence of a catalyst, compound IV and / or its isomers are reacted with a 1,2-o-dihydroxy protecting agent, followed by the introduction of an acyl protecting group, and finally a reduction reaction is carried out in the presence of a reducing agent to obtain compound V and / or its isomers.

[0069] The catalyst is selected from p-toluenesulfonic acid;

[0070] Step 5: Oxidize compound V and / or its isomers in the presence of an oxidizing agent. The resulting oxides are deprotected and cyclized intramolecularly under acidic conditions to obtain compound VI and / or its isomers.

[0071] The oxidant is selected from 2,2,6,6-tetramethylpiperidine-1-oxygen radical (TEMPO);

[0072] Step 6: In the presence of a protective reagent, react compound VI and / or its isomers with R1 to obtain compound VII and / or its isomers;

[0073] The protective agent includes, but is not limited to, N,O-bis(trimethylsilyl)acetamide (BSA);

[0074] Step 7: Remove the protecting group from the sugar ring site of compound VII and / or its isomers under alkaline conditions, and react with 4,4'-dimethoxytriphenylchloro under the catalysis of a catalyst;

[0075] The catalyst includes, but is not limited to, 4-dimethylaminopyridine and / or triethylamine; the solvent for the reaction includes, but is not limited to, dichloromethane or pyridine; the reaction is carried out under the protection of an inert gas, which includes, but is not limited to, nitrogen and / or argon.

[0076] Step 8: Use the product from step 7 to perform a phosphonamide reaction to obtain a nucleoside phosphonamide monomer of a threonine analog with an extended 2'-carbon chain.

[0077] The reaction temperature is 10–50°C (e.g., 11°C, 12°C, 13°C, 15°C, 16°C, 18°C, 20°C, 25°C, 30°C, 32°C, 35°C, 36°C, 38°C, 40°C, 45°C, 46°C, 47°C, 48°C, or 49°C), and the reaction time is 2–12 hours (e.g., 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, or 11 hours). The catalyst for the phosphononamidation reaction includes… However, it is not limited to triethylamine and / or N,N-diisopropylethylamine; the phosphononamidating agent for the phosphononamidation reaction includes 2-cyanoethyl N,N-diisopropylchlorophosphononamide; the temperature of the phosphononamidation reaction is 10 to 25°C (including but not limited to -9°C, -8°C, -5°C, 0°C, 5°C, 10°C, 15°C, 20°C, 21°C, 22°C, 23°C or 24°C), and the time is 1 to 6 hours (e.g., it can be 2 hours, 3 hours, 4 hours or 5 hours);

[0078] In the above steps, the structural formulas of compounds I to VII are shown below, where W1, W2, W3, W4, W5, W6, W7, and W8 are each independently selected from hydrogen or protecting groups:

[0079]

[0080] This invention also provides the application of the nucleoside phosphonamide monomer of the above-mentioned 2'-carbon chain extended threonine analog in the preparation of oligonucleotides. By site-specifically inserting the nucleoside phosphonamide monomer of the 2'-carbon chain extended threonine analog into one position of the oligonucleotide, a functionalized oligonucleotide is obtained. The functionalized oligonucleotide is a nucleoside-modified oligonucleotide with 2'-deoxy-2'-CH2OH-TNA as the backbone, and the nucleoside phosphonamide monomer with 2'-deoxy-2'-CH2OH-TNA as the backbone can be inserted into any position of the oligonucleotide chain.

[0081] The present invention also provides an oligonucleotide, wherein the raw materials for preparing the oligonucleotide include the nucleoside phosphonamide monomer of the above-mentioned 2'-carbon chain extended threonine analog.

[0082] The present invention also provides a method for preparing oligonucleotides, the method comprising synthesizing oligonucleotides using raw materials comprising the above-described sugar ring-modified nucleoside phosphonamide monomers.

[0083] It is understood that common nucleic acid synthesis methods in this field are applicable to this invention.

[0084] Optionally, the synthesis method may include a solid-phase phosphonamide method.

[0085] This invention also provides the application of the above-mentioned 2'-carbon chain extended threonine analog nucleoside phosphonamide monomer or the above-mentioned oligonucleotide in the preparation of nucleic acid drugs, virus detection reagents, RNA localization and imaging reagents or drug delivery systems, wherein the nucleic acid drugs include antisense nucleic acids, small interfering RNA, messenger RNA (mRNA) aptamers and ribozymes, etc.

[0086] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, it should be understood that after reading this description, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined by the appended claims.

[0087] The following examples use instruments and equipment conventional in the art. Experimental methods in the following examples, unless otherwise specified, are generally performed under standard conditions or as recommended by the manufacturer. All raw materials used in the following examples are conventional commercially available products with specifications in the art, unless otherwise stated.

[0088] Example 1

[0089] In this embodiment, taking the synthesis of nucleoside phosphonamide monomers of thymine, cytosine, adenine and guanine as examples, with 2'-deoxy-2'-CH2OH-TNA as the backbone and R1 as the four natural bases and their protective forms, the preparation method of nucleoside phosphonamide monomers of threonine analogs with extended 2'-carbon chains is described in detail. The specific route is shown below.

[0090]

[0091] The reaction conditions for each step are as follows, and the structure of the compound is characterized using nuclear magnetic resonance:

[0092] a: 15 g of 3-benzyloxypropionaldehyde was dissolved in 45 mL of acetonitrile and 5 mL of water. 14 g of ethyl glyoxylate was added at room temperature, followed by the addition of 1 g of L-proline derivative (catalyst) under ice bath conditions. The reaction was then carried out at 5 °C for 60 h. All solvent was removed under reduced pressure, and the resulting slurry was dissolved in 100 mL of methanol. 6 g of sodium borohydride was added at 0 °C. After 30 minutes, the pH of the reaction mixture was adjusted to approximately 7 with concentrated hydrochloric acid. All solvent was removed under reduced pressure, and the mixture was extracted with dichloromethane. The organic phase was washed with water and saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain 14.7 g of a colorless slurry, which is compound 1, with a yield of 60%. The structure of compound 1 was confirmed as follows:

[0093] 1 H NMR (400MHz, CDCl3) δ7.41-7.29(m,6H),4.56(s,2H),4.46-4.40(m,1H),4.26(dt,J=13.8,6.8Hz,2H),3.80(d,J=5.0Hz, 2H),3.70(dd,J=6.6,2.9Hz,2H),3.22(d,J=4.8Hz,1H),2.49-2.40(m,1H),2.09(d,J=15.1Hz,1H),1.31(t,J=7.1Hz,3H);

[0094] 13 C NMR (101MHz, CDCl3) δ174.70,137.93,128.46,127.79,127.73,73.50,70.40,69.21,61.85,61.12,44.40,14.15.

[0095] b: Dissolve 10g of compound 1 in 100mL of tetrahydrofuran, then add 320mg of p-toluenesulfonic acid at room temperature and stir overnight at 25℃. Adjust the pH of the reaction solution to approximately 7 with triethylamine, concentrate, and purify by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain 5.8g of a pale yellow slurry, which is compound 2, with a yield of 70%. The structure of compound 2 is confirmed as follows:

[0096] 1 H NMR (400MHz, CDCl3) δ7.40-7.28(m,5H),4.58-4.49(m,3H),4.39-4.30(m,2H),3.66(d,J=5.0Hz,2H),2.91-2.82(m,1H),2.81(d,J=5.5Hz,1H);

[0097] 13 C NMR (101MHz, CDCl3) δ176.83,137.42,128.59,127.98,127.66,73.59,68.30,66.94,39.39.

[0098] c: Dissolve 6.3 g of compound 2 in 60 mL of tetrahydrofuran. Under ice bath conditions, add 1.6 g of sodium borohydride, followed by 2.3 mL of boron trifluoride diethyl ether. Bring to room temperature and stir at 75 °C for 1 h. Cool the reaction mixture to room temperature, quench the reaction with 1.5 mL of water, remove the solvent under reduced pressure, and purify by silica gel column chromatography (ethyl acetate / methanol = 10 / 1) to obtain 4.1 g of a pale yellow slurry, which is compound 3, with a yield of 65%. The structure of compound 3 is confirmed as follows:

[0099] 1 H NMR (400MHz, DMSO-d6) δ7.24(dd,J=18.1,10.9Hz,5H),4.47-4.28(m,5H),3.63-3.34(m,7H),1.74(dd,J=10.7,5.3Hz,1H);

[0100] 13 C NMR (101MHz, DMSO-d6) δ139.21,128.68,127.80,72.57,70.88,68.90,64.46,59.12,44.30.

[0101] d: Weigh 8.0 g of compound 3 into a 250 mL reaction flask, dissolve it in 60 mL of acetonitrile, add 5.6 mL of 2,2-dimethoxypropane and 121.8 mg of p-toluenesulfonic acid at room temperature, stir overnight at room temperature, adjust the pH of the reaction solution to approximately 7 with triethylamine, concentrate, and extract the slurry with ethyl acetate. Wash the organic phase with water and saturated brine, collect the organic phase, dry it with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain 6.5 g of colorless slurry, which is compound 4, with a yield of 70%. The structural confirmation of compound 4 is as follows:

[0102] 1 H NMR (400MHz, CDCl3) δ7.32(dd,J=16.7,6.0Hz,5H),4.49(s,2H),4.19(dd,J=13.8,7.5Hz,1H),4.08(dd,J=8.3,6.1Hz,1H),3.91-3.76 (m,2H),3.72(t,J=8.0Hz,1H),3.51(qd,J=9.4,6.0Hz,2H),2.73-2.62(m,1H),2.02(dq,J=10.9,5.6Hz,1H),1.41(s,3H),1.36(s,3H);

[0103] 13 C NMR (101MHz, CDCl3) δ137.80,128.49,127.73,108.77,73.50,69.76,68.58,63.22,44.46,26.60,25.57.

[0104] e: Weigh 2g of compound 4 into a 100mL reaction flask, dissolve in 20mL of dichloromethane, then add 2.5mL of pyridine, and add 1.5g of p-methoxybenzoyl chloride under ice bath conditions. Stir at room temperature for 4h to complete the reaction. Extract with dichloromethane, wash the organic phase with dilute hydrochloric acid aqueous solution, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and dissolve the resulting slurry in 150mL of tetrahydrofuran. Add 125mg of palladium hydroxide under a nitrogen atmosphere, and stir the reaction solution under a hydrogen atmosphere for 24h. After the reaction is complete, filter through a diatomaceous earth liner to remove palladium hydroxide, collect the filtrate, concentrate, and purify by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain 1.7g of white crystals, which is compound 5, with a yield of 70%. The structure of compound 5 is confirmed as follows:

[0105] 1 H NMR (400MHz, CDCl3) δ7.99(d,J=8.9Hz,2H),6.93(d,J=8.9Hz,2H),4.59(dd,J=11.4,4.3Hz,1H),4.47(dd,J=11.4,6.8Hz,1H),4.27(dd,J=13.5,7.0Hz, 1H),4.11(dd,J=8.3,6.2Hz,1H),3.87(s,3H),3.85-3.80(m,1H),3.76-3.63 (m,2H),2.45(t,J=6.2Hz,1H),2.22-2.11(m,1H),1.44(s,3H),1.37(s,3H);

[0106] 13 C NMR (101MHz, CDCl3) δ166.84,163.63,131.73,122.20,113.75,108.93,75.01,67.57,62.02,60.66,55.47,44.09,26.60,25.42.

[0107] f: Dissolve 2.8 g of compound 5 in 30 mL of dichloromethane. Add 2.2 g of trichloroisocyanuric acid and 14.1 mg of tetramethoxypiperidine oxide sequentially to the flask with stirring in an ice bath. Continue stirring for 5 minutes, then remove the ice bath and stir at room temperature for 15 minutes to complete the reaction. Filter through a diatomaceous earth liner, collect the filtrate in a separatory funnel, extract with dichloromethane, wash the organic phase first with saturated sodium bicarbonate aqueous solution, then wash with 1 M HCl and saturated saline solution, collect the organic phase, concentrate it, and add 1:4 water and acetic acid to the resulting slurry in an ice bath, stirring overnight at room temperature. Add saturated sodium bicarbonate aqueous solution to the reaction solution until neutral, extract with ethyl acetate, collect the organic phase, dry with anhydrous sodium sulfate, filter, and concentrate. The resulting pale yellow concentrate was dissolved in 30 mL of dichloromethane, followed by the addition of 12 mL of triethylamine, 1.86 mL of acetic anhydride, and a small amount of 4-dimethylaminopyridine. The mixture was stirred at room temperature for 4 h, extracted with dichloromethane, and washed with water and saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain 2.1 g of a pale yellow slurry, which was compound 6, with a yield of 65%. The structural confirmation of compound 6 is as follows (the 1H NMR results are shown in the figure). Figure 1 As shown, the carbon NMR spectrum results are as follows: Figure 2 As shown):

[0108] 1 H NMR (400MHz, CDCl3) δ8.02-7.91(m,2H),6.98-6.87(m,2H),6.25(d,J=0.8Hz,1H),5.15(ddd,J=6.6,4.3,2.5Hz,1H),4.44(ddd,J= 13.8,9.5,5.1Hz,2H),4.39-4.32(m,1H),4.03(dd,J=10.3,4.3Hz,1H),3.86(s,3H),2.83(t,J=5.8Hz,1H),2.10(d,J=1.3Hz,6H);

[0109] 13 C NMR (101MHz, CDCl3) δ170.65,170.16,165.89,163.67,131.78,121.84,113.79,99.93,74.53,73.17,62.17,55.47,50.87,21.23,20.88.

[0110] g: Weigh 0.8 g of compound 6 and 458.1 mg of thymine into a 100 mL reaction flask. Using 15.0 mL of acetonitrile as solvent, add 1.8 mL of N,O-bis(trimethylsilylacetamide). Stir at room temperature until the solution is clear, then add 0.65 mL of trimethylsilyl trifluoromethanesulfonate. React at 60 °C for 30 minutes. After cooling to room temperature, add an appropriate amount of saturated sodium bicarbonate solution until no more bubbles escape. Extract with ethyl acetate, wash with water and saturated brine, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain 0.85 g of colorless foamy solid, which is compound 7a, with a yield of 90%. The structural confirmation of compound 7a is as follows:

[0111] 1 H NMR (400MHz, CDCl3) δ9.08(s,1H),7.96(d,J=8.8Hz,2H),7.31(s,1H),6.91(d,J=8.8Hz,2H),6.07(d,J=3.5Hz,1H),5.30-5.25(m,1H), 4.54(dd,J=9.9,4.4Hz,1H),4.50(dd,J=9.9,4.7Hz,1H),4.30-4.21(m,2H),3.85(s,3H),2.88-2.76(m,1H),2.06(s,3H),1.95(s,3H);

[0112] 13 C NMR (101MHz, CDCl3) δ169.92,165.83,163.74,150.27,135.17,131.77,121. 61,113.84,110.72,88.06,75.56,73.91,62.23,55.49,51.37,20.93,12.72.

[0113] h: 0.8 g of compound 7a was weighed into a 50 mL reaction flask, and 10 mL of ammonia-methanol solution was added at room temperature. The reaction was stirred at room temperature for 3 h until the reaction was complete. Subsequently, all solvents were removed under reduced pressure, and the concentrated solution was purified by silica gel column chromatography (dichloromethane / methanol = 30 / 1) to obtain 0.4 g of a colorless, foamy solid, which was compound 8a, with a yield of 85%. The structural confirmation of compound 8a is as follows:

[0114] 1H NMR (400MHz, DMSO-d6) δ11.27(s,1H),7.71(s,1H),5.85(d,J=3.9Hz,1H),5.35(d,J=3.3Hz,1H),4.90(t,J= 5.0Hz,1H),4.19(s,1H),3.89(dt,J=9.3,6.6Hz,2H),3.51(dd,J=9.4,4.8Hz,2H),2.21(s,1H),1.78(s,3H);

[0115] 13 C NMR (101MHz, DMSO-d6) δ164.27,151.03,137.64,109.51,87.53,75.77,72.26,60.19,55.78,12.81.

[0116] i: Weigh 0.37 g of compound 8a into a 50 mL reaction flask, dissolve it in 8 mL of pyridine, and add 0.67 g of DMTrCl (4,4'-dimethoxytriphenylmethyl chloride) under ice bath conditions. Stir at room temperature for 3 h to complete the reaction. Then, remove all solvents under reduced pressure. Extract the residue with ethyl acetate, wash with water and saturated brine, collect the organic phase, dry it with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 300 / 10 / 1) to obtain 0.67 g of colorless foamy solid, which is compound 9a, with a yield of 80%. The structural confirmation of compound 9a is as follows:

[0117] 1 H NMR (400MHz, CDCl3) δ7.39(d,J=7.8Hz,2H),7.32-7.26(m,6H),7.20(s,2H),6.83(d,J=8.6Hz,4H),5.57(d,J=3.7Hz,1H),4.20(s,1H),4.05(d ,J=10.0Hz,1H),3.93(dd,J=9.8,4.3Hz,1H),3.79(s,6H),3.40(dd,J=9.5,6.4Hz,1H),3.32-3.12(m,2H),2.53(d,J=4.4Hz,1H),1.92(s,3H);

[0118] 13C NMR (101MHz, CDCl3) δ163.46,158.65,150.16,144.45,138.23,135.51,129.97,127. 99,127.04,113.29,110.73,91.53,86.74,76.18,74.20,62.32,55.27,54.05,12.47.

[0119] j: Weigh 85 mg of compound 9a into a 25 mL reaction flask, dissolve in 5 mL of dichloromethane, then add 0.11 mL of N,N-diisopropylethylamine, and add 55.0 μL of 2-cyanoethyl-N,N-diisopropylchlorophosphonamide under ice bath conditions. Stir at room temperature for 3 h to complete the reaction. Extract with dichloromethane, wash the organic phase with saturated sodium bicarbonate aqueous solution, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 800 / 10 / 1) to obtain 88 mg of white foamy solid, which is compound 10a, with a yield of 75%. The phosphorus spectrum characterization results of compound 10a are as follows ( Figure 3 ):

[0120] 31 P NMR (162MHz, CDCl3) δ149.42,149.15.

[0121] k: Weigh 0.1g of compound 6 and N 6 -Bz adenine 101.85 mg was added to a 50 mL reaction flask. Using 8 mL toluene as solvent, 0.2 mL of N,O-bis(trimethylsilylacetamide) was added. The mixture was stirred at 95 °C until the solution became clear. Then, 82 μL of trimethylsilyl trifluoromethanesulfonate was added, and the reaction was carried out at 95 °C for 2 h. After cooling to room temperature, a suitable amount of saturated sodium bicarbonate solution was added until no more bubbles escaped. The mixture was extracted with ethyl acetate, washed with water and saturated brine, and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane / methanol = 40 / 1) to obtain 90 mg of a colorless, foamy solid, which was compound 7b, with a yield of 60%. The structural confirmation of compound 7b is as follows:

[0122] 1H NMR (400MHz, CDCl3) δ8.96(s,1H,),8.74(s,1H),8.29(s,1H),8.03(d,J=7.5Hz,2H),7.95(d,J =8.8Hz,2H),7.62(t,J=7.4Hz,1H),7.53(t,J=7.5Hz,2H),6.91(d,J=8.9Hz,2H),6.41(d,J=3. 2Hz,1H),5.40-5.33(m,1H),4.67(dd,J=11.5,5.6Hz,1H,),4.56(dd,J=11.5,7.2Hz,1H),4.43 (dd,J=10.8,5.1Hz,1H),4.35(dd,J=10.7,2.3Hz,1H),3.85(s,3H),3.41(s,1H),2.06(s,3H);

[0123] 13 C NMR (101MHz, CDCl3) δ170.21,165.86,164.50,163.80,152.77,151.58,149.41,140.96,133.54,132.8 7,131.80,128.92,127.85,123.27,121.45,113.80,87.25,75.25,73.80,62.16,55.50,51.23,20.89.

[0124] l: Weigh 70 mg of compound 7b into a 50 mL reaction flask. Using 3 mL of tetrahydrofuran and 3 mL of methanol as solvents, add 0.26 mL of 1 mol / L sodium hydroxide aqueous solution under ice bath conditions. Stir at room temperature for 1 h to complete the reaction. Add acidic resin to the reaction solution until the pH is neutral. Filter under normal pressure to remove the acidic resin. Purify the concentrated solution by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to obtain 34 mg of colorless foamy solid, which is compound 8b, with a yield of 70%. The structural confirmation of compound 8b is as follows:

[0125] 1H NMR (400MHz, DMSO) δ11.17(s,1H),8.73(s,1H),8.65(s,1H),8.01(d,J=7.4Hz,2H),7.62(t,J=7.3Hz,1H),7.52(t,J=7.7Hz,2H),6.20(d,J=3.8H z,1H),5.56(d,J=4.2Hz,1H),4.97(t,J=5.0Hz,1H),4.29-4.22(m,1H),4 .00(ddd,J=13.0,9.0,4.6Hz,2H),3.65-3.49(m,2H),2.83-2.75(m,1H);

[0126] 13 C NMR (101MHz, DMSO) δ166.06,152.50,152.09,150.74,143.84,133.80,132.93,128.95,126.16,86.40,75.56,71.86,60.02,55.46.

[0127] m: Weigh 0.31 g of compound 8b into a 50 mL reaction flask, dissolve it in 8 mL of pyridine, add 0.44 g of DMTrCl under ice bath conditions, and stir at room temperature for 3 h until the reaction is complete. Then remove all solvents under reduced pressure, extract the residue with ethyl acetate, wash the organic phase with water and saturated brine, collect the organic phase, dry it with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 200 / 10 / 1) to obtain 0.41 g of colorless foamy solid, which is compound 9b, with a yield of 70%.

[0128] The structural confirmation results of compound 9b are as follows:

[0129] 1H NMR (400MHz, CDCl3) δ9.07(s,1H),8.81(s,1H),8.04(d,J=8.1Hz,2H),8.01(s,1H),7.63(t,J=7.3Hz ,1H),7.55(t,J=7.7Hz,2H),7.38(d,J=8.0Hz,2H),7.32-7.19(m,8H),6.82(d,J=8.7Hz,4H),6.69(d, J=10.8Hz,1H),5.84(d,J=3.0Hz,1H),4.22(dd,J=10.7,3.5Hz,1H),4.17(d,J=9.9Hz,1H),4.01(dd,J =9.8,4.0Hz,1H),3.79(s,6H),3.54(dd,J=9.7,5.4Hz,1H),3.30(t,J=9.2Hz,1H),2.95-2.86(m,1H);

[0130] 13 C NMR (101MHz, CDCl3) δ164.42,158.71,151.96,150.17,144.36,143.08,135.50,133.46,132.99,1 29.88,128.97,128.17,127.11,124.40,113.34,89.03,86.80,77.19,74.27,62.73,55.27,54.51.

[0131] n: Weigh 100 mg of compound 9b into a 25 mL reaction flask, dissolve it in 6 mL of dichloromethane, then add 0.11 mL of N,N-diisopropylethylamine, and add 54.0 μL of 2-cyanoethyl-N,N-diisopropylchlorophosphonamide under ice bath conditions. Stir at room temperature for 3 h to complete the reaction. Extract with dichloromethane, wash the organic phase with saturated sodium bicarbonate aqueous solution, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 800 / 10 / 1) to obtain 98 mg of white foamy solid, which is compound 10b, with a yield of 75%. The phosphorus spectrum characterization results of compound 10b are as follows ( Figure 4 ):

[0132] 31 P NMR (162MHz, CDCl3) δ149.47,148.70.

[0133] o: Weigh 0.12g of compound 6 and N 4109.95 mg of -Bz cytosine was added to a 50 mL reaction flask. Using 5 mL of acetonitrile as solvent, 0.29 mL of N,O-bis(trimethylsilylacetamide) was added. The mixture was stirred at 25 °C until the solution became clear. Then, 98 μL of trimethylsilyl trifluoromethanesulfonate was added, and the mixture was stirred at 25 °C for 30 min. The reaction was neutralized with saturated sodium bicarbonate aqueous solution until no more bubbles were produced. The mixture was extracted with ethyl acetate, washed with water and saturated brine, and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane / methanol = 40 / 1) to obtain 0.15 g of a colorless, foamy solid, which was compound 7c, with a yield of 85%. The structure of compound 7c was confirmed as follows:

[0134] 1 H NMR (400MHz, CDCl3) δ8.72(s,1H),8.02(t,J=8.0Hz,3H),7.90(d,J=7.4Hz,2H),7.58(dt,J=15.2,7.4Hz,4H),6.94(d,J=8.9Hz,2H) ,6.08(s,1H),5.35(d,J=3.8Hz,1H),4.71-4.59(m,2H),4.43(dt,J=23.4,7.5Hz,2H),3.87(s,3H),3.02-2.99(m,1H),1.99(s,3H);

[0135] 13 C NMR (101MHz, CDCl3) δ169.81,165.91,163.69,162.43,143.85,133.32,131.83,1 29.12,127.55,121.79,113.85,90.63,75.73,75.64,62.64,55.48,52.20,20.97.

[0136] P: Weigh 0.7 g of compound 7c into a 50 mL pressure-resistant bottle, add 8 mL of ammonia-methanol solution at room temperature, and stir overnight at 50 °C until the reaction is complete. Then remove all solvent under reduced pressure, add dichloromethane to the concentrated solution and sonicate; a slurry-like solid precipitates. After drying, 0.3 g of the slurry-like solid is obtained. Then, using 10 mL of anhydrous methanol as solvent, add 0.7 mL of N,N-dimethylformamide dimethyl acetal at room temperature and react overnight. Concentrate and purify by silica gel column chromatography (dichloromethane / methanol = 10 / 1) to obtain 0.3 g of colorless foamy solid, which is compound 8c, with a yield of 80%. The structural confirmation of compound 8c is as follows:

[0137] 1H NMR (400MHz, CDCl3) δ8.68(s,1H),7.80(d,J=7.2Hz,1H),6.05(d,J=7.2Hz,1H),5.77(d,J=2.8Hz,1H),4.36-4.32(m,1H),4.1 9(dd,J=9.6,1.8Hz,1H),4.12(dd,J=9.7,4.4Hz,1H),3.75(d,J=7.3Hz,2H),3.16(s,3H),3.12(s,3H),2.60(t,J=7.2Hz,1H);

[0138] 13 C NMR (101MHz, CDCl3) δ156.84,146.31,144.84,133.11,102.15,93.06,81.25,78.66,69.76,67.01,53.80,48.80.

[0139] q: Weigh 0.18 g of compound 8c into a 50 mL reaction flask, dissolve it in 8 mL of anhydrous dichloromethane, add 0.26 mL of anhydrous pyridine under ice bath conditions, then add 0.32 g of DMTrCl. Stir at room temperature for 3 h to complete the reaction. Then remove all solvents under reduced pressure, extract the residue with ethyl acetate, wash with water and saturated brine, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 100 / 1 / 0.1) to obtain 0.27 g of colorless foamy solid, which is compound 9c, with a yield of 70%. The structural confirmation of compound 9c is as follows:

[0140] 1 H NMR (400MHz, CDCl3) δ8.78(s,1H),7.36(d,J=7.1Hz,1H),7.31(d,J=7.4Hz,2H),7.21(d d,J=6.6,2.3Hz,6H),7.14(t,J=7.2Hz,1H),6.75(d,J=7.7Hz,4H),5.99(d,J=7.1Hz,1H) ,5.25(d,J=3.1Hz,1H),4.94(d,J=7.4Hz,1H),4.04(d,J=9.1Hz,2H),3.83(dd,J=9.8,4 .5Hz,1H),3.72(s,6H),3.36(dd,J=9.2,6.0Hz,1H),3.09(d,J=7.9Hz,7H),2.80(s,1H).

[0141] 13C NMR (101MHz, CDCl3) δ172.31,158.81,158.57,156.15,145.07,144.59,135.80,135.61,129.95,1 27.99,126.94,113.27,113.26,102.82,95.97,86.49,74.48,63.05,55.26,53.87,41.55,35.26.

[0142] r: Weigh 180 mg of compound 9c into a 50 mL reaction flask, dissolve it in 6 mL of dichloromethane, then add 0.21 mL of N,N-diisopropylethylamine, and add 0.14 mL of 2-cyanoethyl-N,N-diisopropylchlorophosphonamide under ice bath conditions. Stir at room temperature for 3 h to complete the reaction. Extract with dichloromethane, wash the organic phase with saturated sodium bicarbonate aqueous solution, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 800 / 10 / 1) to obtain 170 mg of white foamy solid, which is compound 10c, with a yield of 70%. The phosphorus spectrum characterization results of compound 10c are as follows ( Figure 5 ):

[0143] 31 P NMR (162MHz, CDCl3) δ148.62,148.31.

[0144] s: Weigh 0.3g of O into a 50mL reaction flask. 6 -DPC-N 2 -Ac guanine was reacted under a nitrogen atmosphere with 2.3 mL of 1,2-dichloroethane and 4.6 mL of toluene as solvents, followed by 0.4 mL of N,O-bis(trimethylsilylacetamide). The mixture was stirred at 70 °C until the solution became clear, and the solvent was removed under reduced pressure. The resulting slurry was dissolved in 4 mL of toluene, and then a toluene solution (5 mL) containing 0.23 g of compound 6 was added to the reaction mixture. Subsequently, 0.19 mL of trimethylsilyl trifluoromethanesulfonate was added, and the mixture was stirred at 70 °C for 1 h. After cooling the reaction mixture to room temperature, the reaction was neutralized with a saturated sodium bicarbonate aqueous solution until no more bubbles were produced. The mixture was extracted with ethyl acetate, washed with water and saturated brine, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated. After cooling to room temperature, an appropriate amount of saturated sodium bicarbonate solution was added until no more bubbles escaped. The mixture was extracted with ethyl acetate, washed with water and saturated brine, and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain 260 mg of a colorless, foamy solid, which was compound 7d, with a yield of 60%. The structural confirmation of compound 7d is as follows:

[0145] 1H NMR (400MHz, CDCl3) δ8.18 (s, 1H), 7.87 (d, J = 8.9Hz, 2H), 7.82 (s, 1H), 7.38 (dd, J = 18. 3,10.9Hz,8H),7.27(s,1H),7.24(s,1H),6.90(d,J=8.9Hz,2H),6.23(d,J=3.4Hz,1H) ,5.33(dd,J=5.0,2.5Hz,1H),4.58(ddd,J=18.9,11.5,6.5Hz,2H),4.35(ddd,J=13.3, 10.7,3.9Hz,2H),3.84(s,3H),3.32(dd,J=8.3,6.6Hz,1H),2.49(s,3H),2.06(s,3H).

[0146] 13 C NMR (101MHz, CDCl3) δ170.24,165.77,163.91,156.19,154.33,152.26,150.31,141.80,131. 65,129.24,121.27,121.04,113.96,87.21,75.06,73.64,62.01,55.52,51.20,25.15,20.88.

[0147] t: 0.4 g of compound 7d was weighed into a 50 mL pressure-resistant bottle, and 6 mL of ammonia-methanol solution was added at room temperature. The mixture was stirred at 70 °C for 48 h. Then, all solvent was removed under reduced pressure. The concentrated solution was added to dichloromethane and sonicated, resulting in the precipitation of a white powdery solid. After filtration, 0.12 g of a white solid was obtained. Subsequently, 0.3 mL of N,N-dimethylformamide dimethyl acetal was added to the solution in 8 mL of anhydrous methanol at room temperature and reacted for 36 h. After the reaction was complete, the solution was concentrated, and an appropriate amount of dichloromethane was added and sonicated to obtain 0.12 g of a colorless powdery solid, which was compound 8d, with a yield of 65%. The structural confirmation of compound 8d is as follows:

[0148] 1 H NMR (400MHz, DMSO-d6) δ11.33(s,1H),8.59(s,1H),8.04(s,1H),5.94(d,J=4.0Hz,1H),5.58(s,1H),4.96(s,1H),4.22(s,1H ),3.99(dd,J=8.9,5.4Hz,1H),3.90(dd,J=8.9,4.4Hz,1H),3.64-3.49(m,2H),3.14(s,3H),3.03(s,3H),2.75-2.68(m,1H).

[0149] 13 C NMR (101MHz, DMSO-d6) δ158.55,158.13,157.63,150.09,137.85,120.13,85.80,75.06,72.02,60.22,55.45,41.16,35.10.

[0150] u: Weigh 0.1 g of compound 8d into a 50 mL reaction flask, use 6 mL of LDMF (N,N-dimethylformamide) as solvent, then add 0.1 mL of pyridine, and add 0.16 g of DMTrCl under ice bath conditions. Stir at room temperature for 3 h to complete the reaction. Then remove all solvents under reduced pressure, extract the residue with ethyl acetate, wash with water and saturated brine, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 100 / 1 / 0.1) to obtain 0.18 g of colorless foamy solid, which is compound 9d, with a yield of 90%. The structural confirmation of compound 9d is as follows:

[0151] 1 H NMR (400MHz, DMSO-d6) δ11.37(s,1H),8.44(s,1H),8.13(s,1H),7.26-7.16(m,5H),7.12(d,J=8.0Hz,4H),6.80(d,J=8.6Hz,4H),6.11(d,J =5.4Hz,1H),5.51(s,1H),4.14-4.05(m,1H),3.90(d,J=4.7Hz,2H),3.71(s,6H),3.31-3.24(m,1H),2.99(s,3H),2.90(s,3H),2.87(s,1H).

[0152] 13 C NMR(101MHz,DMSO-d6)δ158.48,158.45,158.39,158.22,157.65,150.12,145.13,137.46,135.94,135.84,130 .10,130.00,128.22,128.02,127.09,119.96,113.54,85.87,85.82,74.29,71.69,62.13,55.46,53.34,35.05.

[0153] v: Weigh 240 mg of compound 9d into a 50 mL reaction flask, dissolve in 8 mL of dichloromethane, then add 0.34 mL of N,N-diisopropylethylamine, and add 0.14 mL of 2-cyanoethyl-N,N-diisopropylchlorophosphineamide under ice bath conditions. Stir at room temperature for 3 h to complete the reaction. Extract with dichloromethane, wash the organic phase with saturated sodium bicarbonate solution, collect the organic phase, dry with anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography (dichloromethane / methanol / triethylamine = 100 / 1 / 1) to obtain 220 mg of white foamy solid, which is compound 10d, with a yield of 70%. The phosphorus spectrum characterization results of compound 10d are as follows ( Figure 6 ):

[0154] 31 P NMR (162MHz, CDCl3) δ149.18,148.76.

[0155] In summary, this invention enables the rapid and efficient preparation of nucleoside phosphonamide monomers of 2'-carbon chain extended threonine analogs. Different nucleoside phosphonamide monomers can be prepared by selecting different bases for R1.

[0156] Example 2

[0157] This embodiment describes the synthesis of fully modified oligonucleotides with 2'-deoxy-2'-CH2OH-TNA as the backbone.

[0158] Based on the nucleoside phosphonamide monomer prepared in Example 1, the nucleoside phosphonamide monomer prepared in Example 1 was inserted into the corresponding oligonucleotide sequence using the standard phosphonamide method on an automated DNA synthesizer, resulting in the fully modified oligonucleotide ON-1 shown below. The molecular weight diagram is as follows. Figure 7 As shown.

[0159] As shown in Table 1, in order to verify the basic biological properties of the modified oligonucleotides (such as enzyme resistance and thermal stability), commercially available natural DNA oligonucleotides with the same sequence, ON-2 and their complementary strands (including natural DNA strand ON-3 and natural RNA strand ON-4; purchased from Sangon Biotech (Shanghai) Co., Ltd.) were purchased as controls.

[0160] Table 1. Oligonucleotide Sequence List

[0161] name sequence Serial Number illustrate ON-1 3'-(CAG GTC ACT ACG)-2' SEQ ID NO.1 2'-Deoxy-2'-CH2OH-TNA ON-2 5'-(CAG GTC ACT ACG)-3' SEQ ID NO.2 Same sequence DNA strand ON-3 3'-(GTC CAG TGA TGC)-5' SEQ ID NO.3 complementary DNA strands ON-4 3'-(GUC CAG UGA UGC)-5' SEQ ID NO.4 Complementary RNA strands

[0162] Example 3

[0163] This embodiment performs a nuclease tolerance experiment.

[0164] Based on the fully modified oligonucleotide ON-1 obtained in Example 2, serum and snake venom phosphodiesterase resistance experiments were conducted.

[0165] (1) Human serum tolerance test

[0166] The fully modified oligonucleotide ON-1 obtained in Example 2 was incubated with DMEM (Dulbecco's Modified Eagle Medium) containing 50% human serum at 37°C for 2 h, 4 h, 6 h, 12 h, 24 h, 48 h, and 72 h, respectively. The reaction was then terminated by adding 10 μL of stop buffer (containing 8 M urea, 5 mM Tris-HCl, and 20 mM EDTA, pH 7.5). Natural DNA oligonucleotide ON-2 was used as a control group. The results were detected by 20% denaturing PAGE gel electrophoresis. Figure 8 YBR GOLD was stained, and the fluorescence intensity of the bands was extracted using Image J to calculate the human serum resistance characteristics of ON-1.

[0167] Experimental results showed that the natural DNA oligonucleotide ON-2 was completely degraded within approximately 30 minutes, while the fully modified oligonucleotide ON-1 obtained in Example 2 of this invention still retained approximately 62% of its intact chain after 72 hours. In human serum, ON-1 exhibited approximately 300 times greater enzyme resistance than ON-2. Furthermore, in Chinese Patent Publication No. CN118271378A, which describes a sugar ring-modified nucleoside phosphoramidide monomer, its preparation method, and its application, the stability of the fully modified oligonucleotide in human serum was only 29 times that of the natural DNA oligonucleotide, while the fully modified oligonucleotide ON-1 obtained in Example 2 of this invention showed an order-of-magnitude difference in enzyme resistance compared to natural DNA.

[0168] (2) Snake venom resistance phosphodiesterase test

[0169] The fully modified oligonucleotide ON-1 obtained in Example 2 was incubated with snake venom phosphodiesterase (0.4 mU / μL) at 37°C for 2 h, 4 h, 6 h, 12 h, 24 h, 48 h, and 72 h, respectively. The reaction was then terminated by adding 10 μL of stop buffer (containing 8 M urea, 5 mM Tris-HCl, 20 mM EDTA, pH 7.5). Natural DNA oligonucleotide ON-2 was used as the control group. The mixture was subjected to 20% denaturing PAGE gel electrophoresis and stained with SYBR Gold. Figure 9 The fluorescence intensity of the bands was extracted using Imaging J to calculate the snake venom resistance phosphodiesterase properties of ON-1.

[0170] Experimental results showed that the natural DNA oligonucleotide ON-2 was also completely degraded within about 30 minutes, while the fully modified oligonucleotide ON-1 obtained in Example 2 of this invention still retained about 67% of its intact strand after 72 hours. In snake venom phosphodiesterase, ON-1 exhibits approximately 400 times greater resistance to the enzyme than ON-2. Furthermore, in Chinese Patent Publication CN118271378A, which describes a sugar ring-modified nucleoside phosphoramidide monomer and its preparation method and application, the fully modified oligonucleotide's resistance to snake venom phosphodiesterase is only 29 times that of the natural DNA oligonucleotide, while the fully modified oligonucleotide ON-1 obtained in Example 2 of this invention shows an order-of-magnitude difference in resistance compared to natural DNA.

[0171] In summary, compared with DNA of the same sequence, the fully modified oligonucleotide ON-1 exhibits an order-of-magnitude improvement in enzyme resistance.

[0172] Example 4

[0173] This embodiment performs a nucleic acid thermostability binding experiment.

[0174] Thermostability binding assays were performed using the fully modified oligonucleotide ON-1 obtained in Example 2. These assays assessed the binding affinity and selectivity by measuring the melting temperatures (Tm values) of the complexes formed by the modified oligonucleotide chain ON-1 with the complementary DNA chain (ON-3) and the complementary RNA chain (ON-4). The experimental procedure is as follows:

[0175] (1) Sample preparation: The complementary DNA strand (ON-3) and complementary RNA strand (ON-4) were diluted to a concentration of 2.5 μM and the concentration was calibrated by UV absorbance (260 nm).

[0176] (2) Complex formation: Mix modified oligonucleotide chain ON-1 and complementary DNA chain (ON-3) and modified oligonucleotide chain ON-1 and complementary RNA chain (ON-4) according to a specific absorbance ratio to ensure uniform concentration.

[0177] (3) Determination of melting curve: A three-stage temperature cycle (heating-cooling-heating again) was adopted, and the absorbance change was monitored at a rate of 0.6~1.2℃ / min. The Tm value was calculated after the data was exported.

[0178] Experimental results show that ( Figure 10The modified oligonucleotide chain ON-1 exhibits significant binding to the complementary RNA chain (S-curve), corresponding to a Tm value of 36.8℃, but no binding to the complementary DNA chain was observed (no S-curve), indicating that this modified oligonucleotide chain has the ability to selectively bind RNA without hybridizing with DNA. Based on this characteristic, the modified oligonucleotide chain ON-1 provided by this invention can be used for disease treatment: for example, targeting RNA viruses, regulating or inhibiting oncogenic miRNAs or long non-coding RNAs through RNA splicing; it can be used for diagnosis and detection: for example, molecular probes for virus detection, high-affinity probes binding to RNA viruses or disease-related RNA biomarkers, or molecular beacons for real-time monitoring of RNA dynamics; it can be used for scientific research: for example, RNA localization and imaging, epigenetic regulation, or gene function research; it can be used for agricultural and industrial production: for example, designing siRNA or ASO to inhibit plant viruses, preparing RNA interference-based pesticides, or regulating the expression of industrial enzymes in microorganisms; it can also be used in emerging fields such as RNA editing and repair, gene editing, or RNA targeting or targeted drug delivery.

[0179] In summary, this invention is based on a molecular design strategy of "glycan ring carbon chain extension - backbone flexibility enhancement". It designs a novel nucleoside phosphonamide monomer with 2'-deoxy-2'-CH2OH-TNA as the backbone. Experiments have shown that the oligonucleotides prepared by it have strong nuclease resistance and can specifically bind to RNA but not DNA. It can provide a novel molecular entity and a new approach for the development of novel antisense nucleic acid systems.

[0180] The applicant declares that the detailed method of the present invention is illustrated by the above embodiments, but the present invention is not limited to the above detailed method, that is, it does not mean that the present invention must rely on the above detailed method to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A nucleoside phosphonamide monomer of a 2'-carbon chain-extended threonine analog, characterized in that, Includes any one of the compounds with the structure shown in Formula 1 or salts of said compounds; in: R1 is selected from any one of natural bases, non-natural bases, modified bases, or their salts; R2 and R3 are each independently selected from alkyl groups having 1 to 4 carbon atoms; DMTr is 4,4'-dimethoxytriphenylmethyl.

2. A method for preparing a nucleoside phosphonamide monomer of a 2'-carbon chain extended threonine analog as described in claim 1, characterized in that, Includes the following steps: Step 1: In the presence of a catalyst, react substrate I with ethyl glyoxylate, and then reduce the resulting product in the presence of a reducing agent to obtain compound II and / or its isomers. Step 2: Compound II and / or its isomers undergo an intramolecular cyclization reaction under acidic conditions, and are then crystallized to obtain compound III and / or its isomers. Step 3: Compound III and / or its isomers undergo a ring-opening reaction in the presence of a reducing agent to obtain compound IV and / or its isomers; Step 4: In the presence of a catalyst, compound IV and / or its isomers are reacted with a 1,2-o-dihydroxy protecting agent, followed by the introduction of an acyl protecting group, and finally a reduction reaction is carried out in the presence of a reducing agent to obtain compound V and / or its isomers. Step 5: Oxidize compound V and / or its isomers in the presence of an oxidizing agent. The resulting oxides are deprotected and cyclized intramolecularly under acidic conditions to obtain compound VI and / or its isomers. Step 6: In the presence of a protective reagent, react compound VI and / or its isomers with R1 to obtain compound VII and / or its isomers; Step 7: Remove the protecting group from the sugar ring site of compound VII and / or its isomers under alkaline conditions, and react them with 4,4'-dimethoxytriphenylchloro under the catalysis of a catalyst; Step 8: Use the product from step 7 to perform a phosphonamide reaction to obtain a nucleoside phosphonamide monomer of a threonine analog with an extended 2'-carbon chain. The structural formulas of compounds I through VII are shown below, where W1, W2, W3, W4, W5, W6, W7, and W8 are each independently selected from hydrogen or protecting groups:

3. The application of the nucleoside phosphonamide monomer of the 2'-carbon chain extended threonine analogue as described in claim 1 in the preparation of oligonucleotides, characterized in that, The enzyme resistance of the oligonucleotide is 300 to 400 times that of the natural oligonucleotide.

4. The application according to claim 3, characterized in that, The oligonucleotide can selectively bind to RNA and does not hybridize with DNA.

5. An oligonucleotide, characterized in that, The raw materials for preparing the oligonucleotide include the nucleoside phosphonamide monomer of the 2'-carbon chain extended threonine analog as described in claim 1.

6. An oligonucleotide according to claim 5, characterized in that, The oligonucleotides are not completely degraded in human serum or snake venom phosphodiesterase for 72 hours.

7. A method for preparing oligonucleotides, characterized in that, The method includes synthesizing oligonucleotides using nucleoside phosphonamide monomers of the 2'-carbon chain extended threonine analogue as described in claim 1.

8. The use of the nucleoside phosphonamide monoclonal analog of the 2'-carbon chain extended threonine nucleic acid analog of claim 1 or the oligonucleotide of any one of claims 5 to 6 in the preparation of nucleic acid drugs, virus detection reagents, RNA localization and imaging reagents or drug delivery systems.

9. The application according to claim 8, characterized in that, The nucleic acid drug is an RNA-targeting drug.

10. A nucleic acid drug composition, characterized in that, The nucleic acid drug composition comprises a nucleoside phosphonamide monomer of a 2'-carbon chain extended threonine analog as described in claim 1, or an oligonucleotide as described in any one of claims 5 to 6.

Citation Information

Patent Citations

  • Sugar ring modified nucleoside phosphoramidite monomer as well as preparation method and application thereof

    CN118271378A